Sabrina Serani

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder versus BCG alone.

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.

Among patients with HR+/HER2+ breast cancer, Herceptin and Perjeta plus endocrine therapy proved to be beneficial without chemotherapy.

The Oncologic Drug Advisory Committee voted that the benefits of imetelstat outweigh the risks for transfusion-dependent myelodysplastic syndrome and anemia.

Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.